Schizophrenia | cpnp.org

Home
About CPNP
- Why Join CPNP
- Board of Directors
- Past Presidents
- Committees & Task Forces
- Awards
- CPNP Foundation
- Corporate Sponsorships
  - Sponsor Program
  - Sponsors
- Information for Patients
- Contact CPNP
Education
- April 2013 Annual Meeting in Colorado Springs, CO
- April 2014 Annual Meeting in Phoenix, AZ
- CPNP University Online Courses
- Drug-Induced Movement Disorders Training DVD
- Psychiatric Pharmacotherapy for Nurses
- Other Meetings
- Find More Resources in My CPNP
  - My CPNP Presentations & Exams
  - My CPNP ACPE Transcript Center
BCPP
- BCPP Exam Preparation
  - BCPP Exam Preparation
  - Certification FAQ
- BCPP Recertification
Careers/Residencies
Member Center
- Member Toolkit
- Email List
- Member Directory
- CPNP Documents and Reports
- Member Hubs
  - Pharmacy Student Hub
  - New Practitioner Hub
Resources
Gov't and Prof Affairs
- Comprehensive Medication Management
- Government Affairs
  - Contacting Legislators and Policy Makers
  - Medicare Coverage Initiative with ACCP
- Position/White Papers
  - Psychiatric Pharmacy Manifesto
  - Psychiatric Pharmacist Integration into the Medical Home Model
My CPNP
- Edit My Profile
- My Disclosures of Interest
- My Workspaces
- My Presentations & Exams
- My Volunteer Profile
- My CPNP Transcript Center
- My Opportunities

Schizophrenia

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002;28(1):75-84. Available at: .

Management of neuroleptic-induced movement disorders: effects of physician training.

Dixon L, Weiden PJ, Frances AJ, Rapkin B. Management of neuroleptic-induced movement disorders: effects of physician training. Am J Psychiatry. 1989;146(1):104-6. Available at: .

Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.

Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94(2):118-24. Available at: .

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001;62(11):878-83. Available at: .

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58(11):1049-52. Available at: .

Is melatonin treatment effective for tardive dyskinesia?

Shamir E, Barak Y, Plopsky I, et al. Is melatonin treatment effective for tardive dyskinesia?. J Clin Psychiatry. 2000;61(8):556-8. Available at: .

Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.

Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648-54. Available at: .

Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.

Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(9):1511-4. Available at: .

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-500. Available at: .

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210. doi:10.1111/j.1742-1241.2010.02587.x.